This report describes and explains the primary biliary cholangitis market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019. The market is expected to grow from $979.47 million in 2024 to $1.49 billion in 2029 at a rate of 8.88%. The market is then expected to grow at a CAGR of 8.73% from 2029 and reach $2.27 billion in 2034.
Growth in the historic period resulted from the increase in smoking, rising demand for personalized medicine, increase in liver transplantation awareness and increasing awareness and early diagnosis. Factors that negatively affected growth in the historic period was regulatory hurdles.
Going forward, the increasing healthcare expenditure, growing geriatric population, surge in liver cancer and favorable government support will drive the growth. Factor that could hinder the growth of the primary biliary cholangitis market in the future include inadequate response to first-line treatment.
The primary biliary cholangitis market is segmented by treatment type into drugs and liver transplantation. The drugs market was the largest segment of the primary biliary cholangitis market segmented by treatment type, accounting for 96.32% or $943.47 million of the total in 2024. Going forward, the drugs segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by treatment type, at a CAGR of 9.05% during 2024-2029.
North America was the largest region in the primary biliary cholangitis market, accounting for 37.46% or $366.89 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the primary biliary cholangitis market will be Asia Pacific and South America where growth will be at CAGRs of 11.54% and 10.80% respectively. These will be followed by Western Europe and Africa where the markets are expected to grow at CAGRs of 8.61% and 7.98% respectively.
The primary biliary cholangitis market is segmented by diagnosis into magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, cholesterol test, antibody tests, liver tests and other diagnoses. The liver tests market was the largest segment of the primary biliary cholangitis market segmented by diagnosis, accounting for 21.02% or $205.87 million of the total in 2024. Going forward, the liver tests segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by diagnosis, at a CAGR of 10.91% during 2024-2029.
The primary biliary cholangitis market is segmented by end user into hospitals, specialty clinics, homecare and other end-users. The hospitals market was the largest segment of the primary biliary cholangitis market segmented by end user, accounting for 47.22% or $462.53 million of the total in 2024. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by end user, at a CAGR of 10.36% during 2024-2029.
The top opportunities in the primary biliary cholangitis market segmented by treatment type will arise in the drugs segment, which will gain $511.63 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by diagnosis will arise in the liver tests segment, which will gain $139.56 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by end user will arise in the hospitals segment, which will gain $247.45 million of global annual sales by 2029. The primary biliary cholangitis market size will gain the most in the USA at $130.97 million.
Market-trend-based strategies for the primary biliary cholangitis market include focus on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care, focus on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC) and focus on adopting strategic partnerships approach to develop advanced treatments.
Player-adopted strategies in the primary biliary cholangitis market include focus on orphan drug designation to the fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the treatment of primary biliary cholangitis (PBC) and focus on introduction of advanced ELISA serum tests for enhanced PBC diagnosis.
To take advantage of the opportunities, the analyst recommends the primary biliary cholangitis companies to focus on combination therapy to improve treatment outcomes, focus on orphan drug development using OCA-bezafibrate combinations, focus on drug development to drive market growth, focus on liver tests to maximize diagnostic market growth, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for drug development and commercialization, provide competitively priced offerings, continue to use B2B promotions and focus on specialty clinics to capture high-growth end-user demand.
The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019. The market is expected to grow from $979.47 million in 2024 to $1.49 billion in 2029 at a rate of 8.88%. The market is then expected to grow at a CAGR of 8.73% from 2029 and reach $2.27 billion in 2034.
Growth in the historic period resulted from the increase in smoking, rising demand for personalized medicine, increase in liver transplantation awareness and increasing awareness and early diagnosis. Factors that negatively affected growth in the historic period was regulatory hurdles.
Going forward, the increasing healthcare expenditure, growing geriatric population, surge in liver cancer and favorable government support will drive the growth. Factor that could hinder the growth of the primary biliary cholangitis market in the future include inadequate response to first-line treatment.
The primary biliary cholangitis market is segmented by treatment type into drugs and liver transplantation. The drugs market was the largest segment of the primary biliary cholangitis market segmented by treatment type, accounting for 96.32% or $943.47 million of the total in 2024. Going forward, the drugs segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by treatment type, at a CAGR of 9.05% during 2024-2029.
North America was the largest region in the primary biliary cholangitis market, accounting for 37.46% or $366.89 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the primary biliary cholangitis market will be Asia Pacific and South America where growth will be at CAGRs of 11.54% and 10.80% respectively. These will be followed by Western Europe and Africa where the markets are expected to grow at CAGRs of 8.61% and 7.98% respectively.
The primary biliary cholangitis market is segmented by diagnosis into magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, cholesterol test, antibody tests, liver tests and other diagnoses. The liver tests market was the largest segment of the primary biliary cholangitis market segmented by diagnosis, accounting for 21.02% or $205.87 million of the total in 2024. Going forward, the liver tests segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by diagnosis, at a CAGR of 10.91% during 2024-2029.
The primary biliary cholangitis market is segmented by end user into hospitals, specialty clinics, homecare and other end-users. The hospitals market was the largest segment of the primary biliary cholangitis market segmented by end user, accounting for 47.22% or $462.53 million of the total in 2024. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by end user, at a CAGR of 10.36% during 2024-2029.
The top opportunities in the primary biliary cholangitis market segmented by treatment type will arise in the drugs segment, which will gain $511.63 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by diagnosis will arise in the liver tests segment, which will gain $139.56 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by end user will arise in the hospitals segment, which will gain $247.45 million of global annual sales by 2029. The primary biliary cholangitis market size will gain the most in the USA at $130.97 million.
Market-trend-based strategies for the primary biliary cholangitis market include focus on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care, focus on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC) and focus on adopting strategic partnerships approach to develop advanced treatments.
Player-adopted strategies in the primary biliary cholangitis market include focus on orphan drug designation to the fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the treatment of primary biliary cholangitis (PBC) and focus on introduction of advanced ELISA serum tests for enhanced PBC diagnosis.
To take advantage of the opportunities, the analyst recommends the primary biliary cholangitis companies to focus on combination therapy to improve treatment outcomes, focus on orphan drug development using OCA-bezafibrate combinations, focus on drug development to drive market growth, focus on liver tests to maximize diagnostic market growth, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for drug development and commercialization, provide competitively priced offerings, continue to use B2B promotions and focus on specialty clinics to capture high-growth end-user demand.
Major Market Trends
- Role of Combination Therapy in Liver Disease Management
- Advancements in Bile Acid Analog-Based Therapies
- Strategic Partnerships Driving Innovation in PBC Treatment
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Primary Biliary Cholangitis Growth Analysis and Strategic Analysis Framework
9 Global Primary Biliary Cholangitis Market Segmentation
10 Primary Biliary Cholangitis Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape and Company Profiles
19 Other Major and Innovative Companies
22 Key Mergers and Acquisitions
23 Recent Development in Primary Biliary Cholangitis Market
24 Opportunities and Strategies
25 Primary Biliary Cholangitis Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Primary Biliary Cholangitis Global Market Opportunities and Strategies to 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global primary biliary cholangitis market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for primary biliary cholangitis? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider primary biliary cholangitis market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment type, by diagnosis and by end user.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional and Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment type, by diagnosis and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by exchange model, by trading type, by coin or token and by payment method in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Market Opportunities and Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations- This section includes recommendations for primary biliary cholangitis providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) by Treatment Type: Drugs; Liver Transplantation2)By Diagnosis: Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) by End User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Key Companies Profiled: Intercept Pharmaceuticals Inc.; Mayo Clinic Laboratories; University of Pittsburgh Medical Center (UPMC); Stanford Health Care; Duke University Hospital
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia; Africa.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa.
Time Series: Five years historic and ten years forecast..
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; primary biliary cholangitis indicators comparison..
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The companies featured in this Primary Biliary Cholangitis market report include:- Intercept Pharmaceuticals Inc.
- Mayo Clinic Laboratories
- University of Pittsburgh Medical Center (UPMC)
- Stanford Health Care
- Duke University Hospital
- UCLA Medical Center
- King's College Hospital
- NewYork-Presbyterian Hospital
- Cleveland Clinic
- Johns Hopkins Hospital
- Gannex Pharma Co., Ltd.
- Gilead Sciences
- Intercept Pharmaceuticals
- Shenzhen Hepalink Pharmaceutical Co., Ltd.
- Chia Tai Tianqing Pharmaceutical
- Zhongshan Pharm
- Lupin Limited
- Jadeite Medicines
- Ipsen SA
- Mitsubishi Tanabe Pharma
- Astellas Pharma
- Takeda Pharmaceutical
- Hanmi Pharmaceutical
- Yuhan Corporation
- Ipsen Global
- COUR Pharmaceuticals
- Abbott Laboratories
- Cadila Pharmaceuticals
- Mylan N.V.
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Novartis AG
- AbbVie
- Hikma Pharmaceuticals PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Genfit S.A.
- Alfasigma S.p.A.
- Calliditas Therapeutics AB
- Glenmark Pharmaceuticals
- ICE Pharma
- Umecrine Cognition AB
- Merck Co
- AstraZeneca
- Sanofi S.A.
- Bristol-Myers Squibb
- Mirum Pharmaceuticals Inc.
- NGM Biopharmaceuticals Inc.
- Fiocruz
- Drag Pharma
- Dipharma
- Clínica Alemana
- Pfizer Brasil
- Glaxosmithkline Brasil
- Novartis Argentina S.A.
- Merck Chile
- AION Labs
- EVA Pharma
- Gensenta
- Eczacıbaşı Group
- Biond Biologics, Diurnal Group
- Er-Kim
- Birgi Mefar Group
- Escient Pharmaceuticals
- TARGET PharmaSolutions Inc.
- HighTide Biopharma Inc.
- CymaBay Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 318 |
| Published | May 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 979.5 Million |
| Forecasted Market Value ( USD | $ 2270 Million |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 69 |
